Opto Circuits Ltd Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and First Nine Months Ended December 31, 2016
February 14, 2017 at 09:32 pm EST
Share
Opto Circuits (India) Ltd. announced unaudited standalone and consolidated earnings results for the third quarter and first nine months ended December 31, 2016. For the quarter, on standalone basis, the company announced net sales or income from operations, net of excise duty was INR 122.963 million compared to INR 217.496 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 9.526 million compared to profit from operations before other income, finance costs and exceptional items of INR 74.055 million a year ago. Loss from ordinary activities before tax was INR 435.406 million compared to INR 34.644 million a year ago. Net loss from ordinary activities after tax was INR 435.406 million or INR 1.80 per basic and diluted share compared to INR 34.149 million or INR 0.14 per basic and diluted share a year ago.
For the first nine months, on standalone basis, the company announced net sales or income from operations, net of excise duty was INR 407.459 million compared to INR 676.832 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 1,669.554 million compared to profit from operations before other income, finance costs and exceptional items of INR 207.663 million a year ago. Loss from ordinary activities before tax was INR 2,907.479 million compared to INR 151.289 million a year ago. Net loss from ordinary activities after tax was INR 2,907.4796 million or INR 12.00 per basic and diluted share compared to INR 155.947 million or INR 0.64 per basic and diluted share a year ago.
For the quarter, on consolidated basis, the company announced net sales or income from operations, net of excise duty was INR 653.352 million compared to INR 480.835 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 140.337 million compared to INR 39.503 million a year ago. Loss from ordinary activities before tax was INR 351.190 million compared to INR 23.477 million a year ago. Net loss for the period after minority interest was INR 351.342 million or INR 1.45 per basic and diluted share compared to INR 13.664 million or INR 0.06 per basic and diluted share a year ago.
For the first nine months, on consolidated basis, the company announced net sales or income from operations, net of excise duty was INR 1,631.319 million compared to INR 2,157.475 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 1,600.738 million compared to profit from operations before other income, finance costs and exceptional items of INR 747.390 million a year ago. Loss from ordinary activities before tax was INR 2,952.410 million compared to profit from ordinary activities before tax of INR 704.688 million a year ago. Net loss for the period after minority interest was INR 2,960.740 million or INR 12.22 per basic and diluted share compared to net profit for the period after minority interest of INR 691.248 million or INR 2.85 per basic and diluted share a year ago.
Opto Circuits (India) Limited is an India-based global medical devices and technology company. The Company and its subsidiaries are engaged in the design, development, manufacture, marketing and distribution of a range of medical products that are used by primary, secondary and tertiary healthcare establishments, as well as in public access facilities, such as fire stations and policy offices in over 150 countries. It specializes in vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies. Its interventional products include stents, balloons and arteriovenous shunts used for the treatment of coronary and peripheral arterial diseases, as well as catheters and implants. Its products include automated patient monitoring devices and services, vital signs monitors, pulse oximeters, and peripheral artery disease diagnostic equipment. It also sells a range of related products and consumables and offers a portfolio of related training and support services.